RARE: Ultragenyx Pharmaceutical Inc.
Performance
RARE -46.43%
Watchlist
Select an item
Summary
RARE at a glance
RARE returned -46.43% over the past year and -27.68% a year over five years. Its worst drop in that year was -64.75%, smaller than 9% of stocks on Redstone, and its Sharpe ratio of -0.30 beats 16% of stocks on Redstone. It pays no dividends.
Current Drawdown
-55.09%
Rolling Volatility
57.95%
Actions
Metrics
Risk Indicators
Alpha-38.68%
Beta1.43x
Sharpe-0.30
Sortino-0.35
Omega0.94
Calmar-0.72
Martin-0.66
Profile
About RARE
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $1.7B
- Listed
- Jan 2014
- Employees
- 1,371
- Headquarters
- Novato, CA
- Website
- ultragenyx.com
Comparisons